An upsurge in research on fibroblast growth factor 21 (FGF21) during the past decade or so – along with the advance of drug candidates targeting nonalcoholic steatohepatitis (NASH) through that mechanism and others – helped Akero Therapeutics Inc. nail down its handsome $65 million series A round as the field evolves.